Elizabeth Martínez-Pérez

Elizabeth Martínez-Pérez

Auto-generated profile, based on publicly available information

Elizabeth Martínez-Pérez

Instituto Oncologico Dr Rosell and PangaeaOncology Lab, Dexeus University Hospital, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2019 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
AHAndrás Hatos
András Hatos
BHBorbála Hajdu-Soltész
Borbála Hajdu-Soltész
AMAlexander Monzon
Alexander Monzon
NPNicolas Palopoli
Nicolas Palopoli
LÁLucía Álvarez
Lucía Álvarez
DPDamiano Piovesan
Damiano Piovesan
The Database of Protein Disorder (DisProt, URL: https://disprot.org) provides manually curated annotations of intrinsically disordered proteins from the literature. Here we report recent developments with DisProt (version 8), including the doubling of protein entries, a new disorder ontology, improvements of the annotation format and a completely new website. The website includes a redesigned graphical interface, a better search engine, a clearer API for programmatic access and a new annotation interface that integrates text mining technologies. The new entry format provides a greater flexibility, simplifies maintenance and allows the capture of more information from the literature. The new disorder ontology has been formalized and made interoperable by adopting the OWL format, as well as its structure and term definitions have been improved. The new annotation interface has made the curation process faster and more effective. We recently showed that new DisProt annotations can be effectively used to train and validate disorder predictors. We believe the growth of DisProt will accelerate, contributing to the improvement of function and disorder predictors and therefore to illuminate the ‘dark’ proteome.

10 December 2020 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
Tamas LazarTamas Lazar
Tamas Lazar
EMElizabeth Martínez-Pérez
Elizabeth Martínez-Pérez
FQFederica Quaglia
Federica Quaglia
AHAndrás Hatos
András Hatos
LCLucía B Chemes
Lucía B Chemes
DPDamiano Piovesan
Damiano Piovesan
The Protein Ensemble Database (PED) (https://proteinensemble.org), which holds structural ensembles of intrinsically disordered proteins (IDPs), has been significantly updated and upgraded since its last release in 2016. The new version, PED 4.0, has been completely redesigned and reimplemented with cutting-edge technology and now holds about six times more data (162 versus 24 entries and 242 versus 60 structural ensembles) and a broader representation of state of the art ensemble generation methods than the previous version. The database has a completely renewed graphical interface with an interactive feature viewer for region-based annotations, and provides a series of descriptors of the qualitative and quantitative properties of the ensembles. High quality of the data is guaranteed by a new submission process, which combines both automatic and manual evaluation steps. A team of biocurators integrate structured metadata describing the ensemble generation methodology, experimental constraints and conditions. A new search engine allows the user to build advanced queries and search all entry fields including cross-references to IDP-related resources such as DisProt, MobiDB, BMRB and SASBDB. We expect that the renewed PED will be useful for researchers interested in the atomic-level understanding of IDP function, and promote the rational, structure-based design of IDP-targeting drugs.

12 January 2021 in Science Signaling
Verified
Journal Article
Closed access
PDF file
BMBálint Mészáros
Bálint Mészáros
HSHugo Sámano-Sánchez
Hugo Sámano-Sánchez
JAJesús Alvarado-Valverde
Jesús Alvarado-Valverde
JČJelena Čalyševa
Jelena Čalyševa
EMElizabeth Martínez-Pérez
Elizabeth Martínez-Pérez
TGToby J. Gibson
Toby J. Gibson
The first reported receptor for SARS-CoV-2 on host cells was the angiotensin-converting enzyme 2 (ACE2). However, the viral spike protein also has an RGD motif, suggesting that cell surface integrins may be co-receptors. We examined the sequences of ACE2 and integrins with the Eukaryotic Linear Motif (ELM) resource and identified candidate short linear motifs (SLiMs) in their short, unstructured, cytosolic tails with potential roles in endocytosis, membrane dynamics, autophagy, cytoskeleton, and cell signaling. These SLiM candidates are highly conserved in vertebrates and may interact with the μ2 subunit of the endocytosis-associated AP2 adaptor complex, as well as with various protein domains (namely, I-BAR, LC3, PDZ, PTB, and SH2) found in human signaling and regulatory proteins. Several motifs overlap in the tail sequences, suggesting that they may act as molecular switches, such as in response to tyrosine phosphorylation status. Candidate LC3-interacting region (LIR) motifs are present in the tails of integrin β3 and ACE2, suggesting that these proteins could directly recruit autophagy components. Our findings identify several molecular links and testable hypotheses that could uncover mechanisms of SARS-CoV-2 attachment, entry, and replication against which it may be possible to develop host-directed therapies that dampen viral infection and disease progression. Several of these SLiMs have now been validated to mediate the predicted peptide interactions.

13 April 2021 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
EMElizabeth Martínez-Pérez
Elizabeth Martínez-Pérez
Miguel Ángel Molina-VilaMiguel Ángel Molina-Vila
Miguel Ángel Molina-Vila
CMCristina Marino-Buslje
Cristina Marino-Buslje
Immune checkpoint blockade (ICB) is becoming standard-of-care in many types of human malignancies, but patient selection is still imperfect. Tumor mutation burden (TMB) is being evaluated as a biomarker for ICB in clinical trials, but most of the sequencing panels used to estimate it are inadequately designed. Here, we present a bioinformatics-based method to select panels and mathematical models for accurate TMB prediction. Our method is based on tumor-specific, forward-step selection of genes, generation of panels using a linear regression algorithm, and rigorous internal and external validation comparing predicted with experimental TMB. As a result, we propose cancer-specific panels for 14 malignancies which can offer reliable, clinically relevant estimates of TMBs. Our work facilitates a better prediction of TMB that can improve the selection of patients for ICB therapy.

19 June 2023 in Protein Science
Verified
Journal Article
Open access
EMElizabeth Martínez‐Pérez
Elizabeth Martínez‐Pérez
MPMatyas Pajkos
Matyas Pajkos
STSilvio Tosatto
Silvio Tosatto
TGToby J. Gibson
Toby J. Gibson
ZDZsuzsanna Dosztanyi
Zsuzsanna Dosztanyi
CMCristina Marino‐Buslje
Cristina Marino‐Buslje
DisProt is the primary repository of Intrinsically Disordered Proteins (IDPs). This database is manually curated and the annotations there have strong experimental support. Currently, DisProt contains a relatively small number of proteins highlighting the importance of transferring annotations regarding verified disorder state and corresponding functions to homologous proteins in other species. In such a way, providing them with highly valuable information to better understand their biological roles. While the principles and practicalities of homology transfer are well‐established for globular proteins, these are largely lacking for disordered proteins. We used DisProt to evaluate the transferability of the annotation terms to orthologous proteins. For each protein, we looked for their orthologs, with the assumption that they will have a similar function. Then, for each protein and their orthologs, we made multiple sequence alignments (MSAs). Disordered sequences are fast evolving and can be hard to align, therefore, we implemented alignment quality control steps ensuring robust alignments before mapping the annotations. We have designed a pipeline to obtain good‐quality MSAs and to transfer annotations from any protein to their orthologs. Applying the pipeline to DisProt proteins, from the 1731 entries with 5623 annotations, we can reach 97,555 orthologs and transfer a total of 301,190 terms by homology. We also provide a web server for consulting the results of DisProt proteins and execute the pipeline for any other protein. The server Homology Transfer IDP (HoTIDP) is accessible at http://hotidp.leloir.org.ar.

24 July 2026 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
MGMaria Gonzalez-Cao
Maria Gonzalez-Cao
MSMarta Sisteré-Oró
Marta Sisteré-Oró
TMTeresa Moran
Teresa Moran
NRNoemi Reguart
Noemi Reguart
RCRaquel Cabezon
Raquel Cabezon
DBDaniel Benitez-Ribas
Daniel Benitez-Ribas
Background: Despite the incorporation of atezolizumab, an anti-programmed death-ligand 1 (PD-L1) antibody, into first-line chemotherapy regimen, survival in patients with extensive-stage small cell lung cancer (ES-SCLC) remains poor. Given the role of dendritic cells (DCs) in modulating responses to anti-programmed cell death protein 1 (PD-1) antibodies, a promising avenue is the development of vaccines based on DCs, together with the evaluation of how DC phenotypic modifications shape treatment efficacy. Materials and methods: This is a single-arm, phase Ib/II, open-label clinical trial investigating the safety and activity of combining autologous tumor lysate pulsed DCs administered intradermally with intravenous atezolizumab as maintenance therapy for patients with ES-SCLC. Following leukapheresis, monocytes were differentiated ex vivo into mature DCs and loaded with irradiated autologous tumor lysate. After standard induction therapy (four cycles of carboplatin, etoposide, and atezolizumab), patients received up to six doses of mature DCs intradermally, along with intravenous atezolizumab 1,200 mg every 3 weeks, until disease progression. Results: 20 patients were enrolled, including six patients with brain metastases. 18 patients received DC vaccination, with a median of three doses (range 1–6). Most grade 3–4 treatment-related adverse events were hematological and related to chemotherapy. DC vaccination was well tolerated, with only grade 1–2 transient skin irritation at the injection site. Among 18 evaluable patients, 17 (94.4%) achieved an objective response. After a median follow-up of 31.4 months, progression-free survival at 2 years (PFS 2y ) was 20% (95% CI 6.4% to 39.1%), median overall survival (OS) 11.2 months (95% CI 6.3 to 26.0) and OS 3y 22.5% (95% CI 6.8% to 43.6%). Six patients achieved long survival (median 30.5 months, range 23.4–36.2). Expansion of conventional type DC1 (cDC1s) XCR1 + and stem-like progenitor-exhausted (CXCR5 + PD-1 + ) CD8 + T cells following chemotherapy plus atezolizumab was associated with improved PFS (HR 0.94, 95% CI 0.90 to 0.99 and HR 0.59, 95% CI 0.39 to 0.89). Conclusion: DC immunization combined with atezolizumab maintenance following standard chemotherapy plus atezolizumab treatment is well tolerated. Its clinical activity cannot be definitively determined in this study, as it was administered as maintenance therapy; however, the observed rate of long-term survivors suggests a potential benefit. Our findings suggest a pivotal role for cDC1s in mediating the antitumor activity in long-term survivors. Trial registration number: NCT04487756 .